Credit Suisse Group Reiterates Hold Rating for Eli Lilly and (LLY)

Credit Suisse Group restated their hold rating on shares of Eli Lilly and (NYSE:LLY) in a report published on Friday, February 2nd. Credit Suisse Group currently has a $80.00 target price on the stock.

A number of other research analysts have also recently weighed in on the company. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a sell rating in a research report on Tuesday, October 24th. Barclays lifted their price objective on Eli Lilly and from $90.00 to $98.00 and gave the stock an overweight rating in a research report on Friday, October 13th. Berenberg Bank reiterated a buy rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research cut Eli Lilly and from a buy rating to a hold rating in a research report on Monday, October 30th. Finally, Leerink Swann lifted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the stock a market perform rating in a research report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. Eli Lilly and currently has an average rating of Hold and an average price target of $92.02.

Shares of Eli Lilly and (NYSE:LLY) opened at $76.40 on Friday. Eli Lilly and has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $84,020.00, a price-to-earnings ratio of -381.55, a P/E/G ratio of 1.39 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last released its earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same quarter last year, the company earned $0.95 earnings per share. Eli Lilly and’s quarterly revenue was up 7.0% compared to the same quarter last year. analysts anticipate that Eli Lilly and will post 4.88 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.95%. Eli Lilly and’s payout ratio is -1,040.00%.

In other Eli Lilly and news, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the sale, the insider now directly owns 4,130 shares in the company, valued at approximately $334,901.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.12, for a total value of $780,780.00. Following the sale, the senior vice president now owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders have sold a total of 259,610 shares of company stock worth $22,727,406 over the last three months. 0.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of LLY. Beach Investment Management LLC. purchased a new stake in Eli Lilly and during the 2nd quarter worth approximately $400,000. National Planning Corp increased its holdings in shares of Eli Lilly and by 8.4% in the 2nd quarter. National Planning Corp now owns 9,478 shares of the company’s stock valued at $784,000 after acquiring an additional 737 shares during the last quarter. Partnervest Advisory Services LLC increased its holdings in shares of Eli Lilly and by 13.3% in the 2nd quarter. Partnervest Advisory Services LLC now owns 6,595 shares of the company’s stock valued at $543,000 after acquiring an additional 775 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Eli Lilly and by 73.1% in the 2nd quarter. First Trust Advisors LP now owns 396,730 shares of the company’s stock valued at $32,651,000 after acquiring an additional 167,537 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Eli Lilly and by 1.3% in the 2nd quarter. Rhumbline Advisers now owns 1,599,864 shares of the company’s stock valued at $131,669,000 after acquiring an additional 20,873 shares during the last quarter. Institutional investors own 76.20% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/13/eli-lilly-and-lly-given-hold-rating-at-credit-suisse-group.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply